GERD 3: Acid Pocket, Endoscopy, and the Initial Approach

Episode keywords: acid pocket GERD, LA classification reflux esophagitis, Barrett's esophagus screening ACG AGA, empiric PPI trial, alarm symptoms GERD, non-erosive reflux disease endoscopy, lifestyle modifications GERD, alginates GERD mechanism

Episode Summary

The acid pocket explains why Barrett's esophagus develops specifically at the GEJ rather than randomly throughout the esophagus. This episode covers the postprandial acid pocket and its role in genotoxic injury, the LA classification of reflux esophagitis and which grades actually confirm GERD, why only 30% of heartburn patients have visible esophagitis, the ACG versus AGA Barrett's screening criteria, and the full initial management approach including lifestyle modifications and the pharmacologic options before PPIs.

Key Topics

• The acid pocket: After meals, a layer of newly secreted, unbuffered acid sits on top of gastric contents at the cardia. The Z-line (squamocolumnar junction) is exposed to this acid for more than 10% of the day even in healthy people. In hiatal hernia, the acid pocket migrates above the diaphragm. Dietary nitrate is concentrated in saliva, swallowed, and reduced to nitrite by oral bacteria. When nitrite contacts the acid pocket, it generates nitric oxide and reactive nitrogen species that are genotoxic. The GEJ is therefore simultaneously exposed to acid-peptic injury and nitrosative stress. This dual insult drives intestinal metaplasia at the cardia specifically.
• Three questions endoscopy answers in GERD: Is there reflux esophagitis? Is there a peptic stricture? Is there Barrett's esophagus? Endoscopy does not confirm GERD in a patient with typical symptoms and complete PPI response. That is a clinical diagnosis.
• LA classification: Grade A is mucosal breaks less than 5 mm not extending between fold tops. Grade B is mucosal breaks greater than 5 mm not extending between fold tops. Grade C extends between two or more fold tops but involves less than 75% of circumference. Grade D involves 75% or more of circumference. Grades B through D confirm GERD. Grade A has poor interobserver agreement and can be seen in asymptomatic individuals; it alone does not definitively confirm pathologic reflux.
• The 30% statistic: Only about 30% of patients with frequent heartburn have endoscopic esophagitis. The majority have non-erosive reflux disease. Heartburn severity does not predict esophagitis severity. Symptoms and mucosal damage are poorly correlated.
• Empiric PPI trial: For classic heartburn and regurgitation without alarm symptoms, start an 8-week empiric PPI trial taken 30 to 60 minutes before a meal. Do not scope first. Stop PPIs 2 to 4 weeks before any diagnostic endoscopy; active PPI therapy heals esophagitis and can also mask eosinophilic esophagitis.
• Alarm symptoms requiring endoscopy: Dysphagia, odynophagia, weight loss, GI bleeding, anemia, vomiting. These bypass empiric therapy.
• Barrett's screening -- ACG vs AGA: ACG recommends a single screening EGD for patients with chronic GERD symptoms plus three or more additional risk factors (male sex, age over 50, white race, tobacco use, obesity, family history of Barrett's or esophageal adenocarcinoma). ACG generally does not recommend screening women without multiple risk factors. AGA 2022 considers chronic GERD as one risk factor among many and recommends screening when three or more total risk factors are present, so a white male over 50 with obesity could qualify even without documented GERD symptoms.
• Lifestyle modifications (8 items boards test): Elevate head of bed 6 to 8 inches with blocks (not pillows). Lose weight. Avoid recumbency for 2 to 3 hours after meals. Avoid right-lateral decubitus sleeping (left-lateral keeps the acid pocket below the esophageal inlet). No bedtime snacks. Avoid trigger foods (chocolate, coffee, alcohol, fatty foods). No smoking or alcohol. Avoid medications that reduce LES pressure (calcium channel blockers, nitrates, anticholinergics, theophylline). Evidence for most is limited; weight loss and head-of-bed elevation have the strongest data.
• Other medical options: Alginates form a gel raft on top of gastric contents, physically displacing the acid pocket from the GEJ -- a direct mechanical intervention targeting pathophysiology. Prokinetics (metoclopramide) are no longer recommended; side effect rates approach 30%, including tardive dyskinesia. Baclofen reduces TLESRs but CNS side effects limit clinical utility.

Board Pearls

Board trap: AGA versus ACG Barrett's screening. A 55-year-old white male with obesity and family history of esophageal adenocarcinoma but no GERD symptoms. Under AGA (four risk factors), screening is appropriate. Under ACG, possibly not without chronic GERD.
High-yield: Stop PPIs 2 to 4 weeks before a diagnostic endoscopy. Active PPI therapy heals esophagitis (producing false-negative for erosive disease) and suppresses eosinophilic esophagitis features (producing false-negative for EoE).
Board trap: LA Grade A is not confirmatory for GERD. Only LA-B through D represent objective evidence of pathologic reflux on endoscopy.